Your browser doesn't support javascript.
loading
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen, Mikael; Mondot, Lydiane; Bucciarelli, Florence; Pignolet, Béatrice; Laplaud, David-Axel; Wiertlewski, Sandrine; Brochet, Bruno; Ruet, Aurélie; Defer, Gilles; Derache, Nathalie; Vermersch, Patrick; Zephir, Hélène; Debouverie, Marc; Mathey, Guillaume; Berger, Eric; Cappé, Chrystelle; Labauge, Pierre; Carra, Clarisse; De Seze, Jérôme; Bigaut, Kevin; Brassat, David; Lebrun-Frenay, Christine.
Afiliação
  • Cohen M; Service de Neurologie, CRCSEP, Unité de Recherche Clinique Cote d'Azur (UR2CA), Centre Hospitalier Universitaire Pasteur 2, Nice, France.
  • Mondot L; Service de Radiologie, Unité de Recherche Clinique Cote d'Azur (UR2CA), Centre Hospitalier Universitaire Pasteur 2, Nice, France.
  • Bucciarelli F; Neurosciences Department, CRCSEP, University Hospital of Toulouse, Toulouse, France/INSERM U1043-CNRS UMR 5282, Centre de Physiopathologie Toulouse, Toulouse, France.
  • Pignolet B; Neurosciences Department, CRCSEP, University Hospital of Toulouse, Toulouse, France/INSERM U1043-CNRS UMR 5282, Centre de Physiopathologie Toulouse, Toulouse, France.
  • Laplaud DA; CRTI-INSERM U1064, CIC 1413, Service de Neurologie, CHU Nantes, Nantes, France.
  • Wiertlewski S; CRTI-INSERM U1064, CIC 1413, Service de Neurologie, CHU Nantes, Nantes, France.
  • Brochet B; Service de Neurologie, CRC SEP, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.
  • Ruet A; Service de Neurologie, CRC SEP, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.
  • Defer G; Service de Neurologie, CHU de Caen, Avenue de la Côte de Nacre, Caen, France.
  • Derache N; Service de Neurologie, CHU de Caen, Avenue de la Côte de Nacre, Caen, France.
  • Vermersch P; Univ. Lille, INSERM U1172, CHU Lille, FHU Imminent, Lille, France.
  • Zephir H; Univ. Lille, INSERM U1172, CHU Lille, FHU Imminent, Lille, France.
  • Debouverie M; CHRU-Nancy, INSERM, Université de Lorraine, CIC, Epidémiologie Clinique, Nancy, France.
  • Mathey G; CHRU-Nancy, INSERM, Université de Lorraine, CIC, Epidémiologie Clinique, Nancy, France.
  • Berger E; Service de Neurologie, CHU de Besançon, Besançon, France.
  • Cappé C; Centre d'investigation clinique, CHU de Besançon, Besançon, France.
  • Labauge P; CHU de Montpellier, MS Unit, Montpellier, France.
  • Carra C; CHU de Montpellier, MS Unit, Montpellier, France.
  • De Seze J; Clinical Investigation Center, Department of Neurology, CHU de Strasbourg, INSERM 1434, Strasbourg, France.
  • Bigaut K; Clinical Investigation Center, Department of Neurology, CHU de Strasbourg, INSERM 1434, Strasbourg, France.
  • Brassat D; Neurosciences Department, CRCSEP, University Hospital of Toulouse, Toulouse, France/INSERM U1043-CNRS UMR 5282, Centre de Physiopathologie Toulouse, Toulouse, France.
  • Lebrun-Frenay C; Service de Neurologie, CRCSEP, Unité de Recherche Clinique Cote d'Azur (UR2CA), Centre Hospitalier Universitaire Pasteur 2, Nice, France.
Mult Scler ; 27(10): 1556-1563, 2021 09.
Article em En | MEDLINE | ID: mdl-33124504
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article